Effect of HLA-DPA1 alleles on chronic hepatitis B prognosis and treatment response

Related Experiment Video

Updated: Mar 6, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Seyma Katrinli1, Feruze Yilmaz Enc2, Kamil Ozdil3

  • 1Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey.

Northern Clinics of Istanbul
|March 10, 2017
PubMed

Insights

The HLA-DPA1*04:01 allele may increase the risk of chronic hepatitis B (CHB) recurrence after hepatitis B e antigen (HBeAg) seroconversion. This specific allele was more common in patients who experienced disease reoccurrence.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis B (CHB) poses a significant global health challenge.
  • Hepatitis B virus (HBV) infection outcomes are influenced by human leukocyte antigen (HLA) variations.
  • HLA-DPA1 alleles are implicated in the course of HBV infection.

Purpose of the Study:

  • To examine the association between HLA-DPA1 alleles and treatment response in CHB patients.
  • To investigate the link between HLA-DPA1 alleles and hepatitis B e antigen (HBeAg) seroconversion.
  • To determine if HLA-DPA1 alleles correlate with disease recurrence post-HBeAg loss.

Main Methods:

  • Genotyping of eight HLA-DPA1 alleles in 246 CHB patients using high-resolution polymerase chain reaction with sequence-specific primers.
  • Analysis of associations with treatment response, cirrhosis development, HBeAg seroconversion, and disease recurrence.
  • Statistical analysis including Fisher's exact test for significance.

Main Results:

  • No significant association was found between HLA-DPA1 alleles and treatment response, cirrhosis development, or HBeAg seroconversion.
  • The HLA-DPA1*04:01 allele was significantly more prevalent in patients who experienced disease reoccurrence after HBeAg seroconversion (100% vs. 36.8%, p=0.037).

Conclusions:

  • The HLA-DPA1*04:01 allele may serve as a predictive marker for CHB reoccurrence.
  • Further research is warranted to elucidate the mechanisms underlying this association.
  • Understanding HLA-DPA1 associations can inform personalized management strategies for CHB.
Abstract

Keywords:
Chronic hepatitis BHBeAg seroconversionHLA-DPA1cirrhosistreatment response

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
273
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56